News

Arialys Therapeutics Announces U.S. FDA Fast Track Designation for ART5803, the First Precision Therapeutic Candidate in Development for the Treatment of Anti-NMDA Receptor Encephalitis

Arialys Therapeutics Announces First ANRE Patient Treated with ART5803 in Open-Label Phase 2 Study and FDA Clearance of IND for Randomized Phase 2 Study

Arialys Presents Phase 1 ART5803 Data at AAN 2026

January 15, 2026

Arialys Presents Novel Anti-NMDAR Autoantibody Assay Data at ACNP 2026 Annual Meeting

September 25, 2025

Arialys Therapeutics Receives FDA Rare Pediatric Disease Designation for ART5803 to Treat Anti-NMDA Receptor Encephalitis

Arialys Therapeutics Publishes Preclinical Data in Nature Communications Supporting ART5803 as a First-in-Class Precision Therapeutic for Anti-NMDA Receptor Autoimmune Neuropsychiatric Disease